Sezary Syndrome
Watchlist
Retrieved
2022-04-26
Source
Trials
—
Genes
TNFRSF1B,
CCR4,
TP53,
PLCG1,
PTEN,
ZEB1,
CDKN2A,
IL32,
CD28,
ARID1A,
KMT2C,
IL2RG,
CHD3,
CREBBP,
CDKN1B,
PRKG1,
KMT2D,
SMARCA4,
CTLA4,
RB1,
DNMT3A,
BRAF,
CARD11,
TET2,
BRD9,
MAPK1,
RPS6KA1,
BCL10,
TRBV20OR9-2,
TNFRSF8
TNFRSF1B,
CCR4,
TP53,
PLCG1,
PTEN,
ZEB1,
CDKN2A,
IL32,
CD28,
ARID1A,
KMT2C,
IL2RG,
CHD3,
CREBBP,
CDKN1B,
PRKG1,
KMT2D,
SMARCA4,
CTLA4,
RB1,
DNMT3A,
BRAF,
CARD11,
TET2,
BRD9,
MAPK1,
RPS6KA1,
BCL10,
TRBV20OR9-2,
TNFRSF8,
KIR3DL2,
DPP4,
IL2,
PLS3,
TOX,
IL4,
IL7,
IL10,
IL17A,
FOXP3,
TSPYL2,
STAT3,
LINC02605,
CCR10,
TWIST1,
TNF,
PTPN6,
CD164,
NR0B2,
CDR3,
SATB1,
PIK3CA,
KLRK1,
STAT5A,
STAT5B,
TRBV16,
TRB,
TRBV7-9,
TRBC1,
IL22,
TNFAIP3,
JUNB,
BCR,
NAV3,
EPHA4,
CDKN2B,
IL21,
IFNG,
IL5,
AHI1,
MIR21,
RUNX3,
FCRL3,
JAK3,
AKT1,
MIR486-1,
MIR214,
TNFSF11,
IER3,
IL18R1,
TNFRSF1A,
TNFRSF10B,
KLRC4-KLRK1,
TNFSF10,
CMTM2,
CRISP2,
TIGIT,
PRSS55,
IL31,
MIR342,
ARHGEF7,
ZNF217,
MIR223,
MIR155,
SOCS3,
IL17F,
NEDD4L,
TBX21,
TRAC,
TRAJ60,
TRAV29DV5,
ASCC1,
IL23A,
RTEL1,
DNM3,
POT1,
CADM1,
PDCD10,
SPZ1,
LILRB1,
CXCL13,
EBI3,
SLFN12,
MYDGF,
NCR1,
KLHL42,
IL25,
HM13,
IL21R,
ABL1,
CCL19,
THBS1,
FGFR1,
GATA6,
HELLS,
HHEX,
HLA-DQB1,
HLA-G,
HRAS,
IKBKB,
CXCL8,
IL13,
IL15,
CXCL10,
JAK2,
JUND,
KIR2DL1,
KIR2DL3,
GATA3,
ERBB2,
LBR,
CTSB,
BIN1,
ANXA5,
FAS,
ARRB2,
ATM,
CCND1,
CBL,
CD4,
CD40,
CD40LG,
CD44,
CD47,
CDO1,
CCR7,
CNC2,
KRAS,
LCK,
TGFBR2,
RRBP1,
CCL17,
PARP1,
CCL21,
SDC4,
SELL,
SELPLG,
SLC8A1,
SMARCA1,
SMARCB1,
SOAT1,
STAT4,
TAC1,
TCF3,
TRA,
TGFB1,
CCL5,
RAG2,
MDM2,
RAF1,
MTAP,
MYBL2,
MYC,
MYCL,
NFKB1,
NKG7,
NRAS,
NTRK1,
PAK1,
PAM,
PIK3CB,
PIK3CD,
PIK3CG,
PPP1R1A,
PRKAR1A,
H3P40
Drugs
A-dmDT390-bisFv(UCHT1),
Adenovirus-Interferon gamma - coding DNA sequence,
Alisertib,
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus,
Belinostat
(
BELEODAQ
),
Brentuximab vedotin
(
ADCETRIS
),
Chlormethine
(
Ledaga
),
Darinaparsin,
Denileukin diftitox,
Fenretinide,
Forodesine hydrochloride,
Human monoclonal antibody against CD4,
Humanised IgG1 monoclonal antibody against human KIR3DL2,
Iodine (131I) tositumomab,
Miltefosine
(
IMPAVIDO
),
Mogamulizumab
(
POTELIGEO
),
N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin)benzamide,
Naloxone hydrochloride dihydrate,
Panobinostat
(
FARYDAK
),
Pralatrexate
(
FOLOTYN
),
Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein,
Resiquimod,
Romidepsin
(
ISTODAX
),
Siplizumab,
Suberolylanilide hydroxamic acid,
Synthetic hypericin,
Vorinostat
(
ZOLINZA
),
Zanolimumab,
haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate
Registered!
Sezary syndrome is an aggressive form of cutaneous T-cell lymphoma which is a group of disorders that occur when T-cells (a type of white blood cell) become cancerous and affect the skin. It is characterized by a widespread red rash that may cover most of the body, the presence of cancerous T cells (called Sezary cells) in the blood, and abnormally enlarged lymph nodes. Other signs and symptoms may include intense itchiness, scaling and peeling of the skin; fever; weight loss; hair loss; outward turning of the eyelids (ectropion); palmoplantar keratoderma; malformation of the nails; and hepatosplenomegaly. The exact cause of Sezary syndrome is currently unknown. Treatment varies based on the signs and symptoms present in each person and the severity of the condition.